Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease

Blood

Volumn 121, Issue 16, 2013, Pages 3274-3283

  Le Huu, Doanh ^a   Matsushita, Takashi ^a   Jin, Guihua ^a   Hamaguchi, Yasuhito ^a   Hasegawa, Minoru ^a   Takehara, Kazuhiko ^a   Tedder, Thomas F ^b   Fujimoto, Manabu ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; CD19 ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; LATENCY ASSOCIATED PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; CD11B ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY B LYMPHOCYTE; SCLERODERMA; SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WILD TYPE MOUSE; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; FIBROSIS; GENE DELETION; GENETICS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; PATHOLOGY; SKIN; SYSTEMIC SCLEROSIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD19; ANTIGENS, CD1D; ANTIGENS, CD5; B-LYMPHOCYTES, REGULATORY; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; FEMALE; FIBROSIS; GENE DELETION; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES;

MLCS; MLOWN;

EID: 84879154724     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-465658     Document Type: Article

References (49)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674): 1550-1561.
2. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125(4): 435-454.
3. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77(1):1-12.
4. Yamamoto T. Characteristics of Animal Models for Scleroderma. Curr Rheumatol Rev. 2005;1(1): 101-109.
5. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919-4927.
6. Zhang C, Todorov I, Zhang Z, et al. Donor CD41 T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107(7):2993-3001.
7. Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD41 T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189(1):222-233.
8. Matte-Martone C, Wang X, Anderson B, et al. Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant. 2010;16(9):1222-1230.
9. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34(3):389-396.
10. Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
11. Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011; 117(7):2275-2283.
12. Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119(25): 6145-6154.
13. Davis JE, Ritchie DS. B cells in GVHD: friend or foe? Blood. 2010;115(12):2558-2559, author reply 2559-2560.
14. Lee KM, Kim JI, Stott R, et al. Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant. 2012;12(8):2072-2078.
15. Heidt S, Hester J, Shankar S, Friend PJ, Wood KJ. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant. 2012;12(7):1784-1792.
16. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006;108(7):2485-2492.
17. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5): 1570-1580.
18. Watanabe R, Fujimoto M, Ishiura N, et al. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol. 2007; 171(2):560-570.
19. Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010;184(9):4801-4809.
20. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009;182(12):7459-7472.
21. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010;1183:38-57.
22. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol. 2010;185(4):2240-2252.
23. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541.
24. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, Sato S. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol. 2011;178(2):735-743.
25. Yang M, Deng J, Liu Y, et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol. 2012;180(6):2375-2385.
26. Matsushita T, Fujimoto M, Hasegawa M, Komura K, Takehara K, Tedder TF, Sato S. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol. 2006;168(3): 812-821.
27. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD51 phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639-650.
28. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3(1):39-50.
29. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol. 2012;132(12): 2752-2761.
30. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, Shlomchik WD. Memory CD41 T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101-108.
31. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168(6): 3088-3098.
32. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14(4):365-378.
33. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163(10):5693-5699.
34. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583-594.
35. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139(8):2511-2515.
36. Grogan BM, Tabellini L, Storer B, et al. Activation and expansion of CD8(1) T effector cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(8): 1121-1132.
37. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2003;121(4):713-719.
38. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127(2):281-292.
39. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci. 2008;49(2):103-113.
40. Khalil N. TGF-beta: from latent to active. Microbes Infect. 1999;1(15):1255-1263.
41. Takeshita A, Chen Y, Watanabe A, Kitano S, Hanazawa S. TGF-beta induces expression of monocyte chemoattractant JE/monocyte chemoattractant protein 1 via transcriptional factor AP-1 induced by protein kinase in osteoblastic cells. J Immunol. 1995;155(1):419-426.
42. Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int. 2000;57(3):1002-1014.
43. Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180(7): 4763-4773.
44. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci USA. 2007;104(35): 14080-14085.
45. Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264-268.
46. Chang PP, Barral P, Fitch J, et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol. 2011;13(1):35-43.
47. King IL, Fortier A, Tighe M, et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat Immunol. 2011;13(1):44-50.
48. Allen JL, Fore MS, Wooten J, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012;120(12):2529-2536.
49. Yang M, Sun L, Wang S, et al. Novel function of B cell-activating factor in the induction of IL-10producing regulatory B cells. J Immunol. 2010; 184(7):3321-3325.